The investigators reported the rates of poor outcomes in patients with hrSCC treated with MMS alone, and explored specific clinical factors that may be more predictive of these outcomes.

Researchers analyzed the effect of brimonidine in vitro, in vivo, and in a randomized exploratory trial and found that brimonidine reduces inflammation and erythema in rosacea by affecting the processes of neurogenic activation and neutrophil recruitment.

The change from baseline in 2-hour pruritus score was shown to be statistically noninferior from IV cetirizine to IV diphenhydramine, in favor of IV cetirizine.

Patients with hereditary angioedema who received lanadelumab exhibited few cases of hypersensitivity and had low immunogenicity.

The use of resiquimod gel 0.03%/0.01% is effective for the treatment of patients with actinic keratosis.

The prevalence of depression in patients with atopic dermatitis was higher than in those without atopic dermatitis.

The members reached consensus on the use of a 5-point ordinal scale with descriptors provided via referenced electronic platforms.

Compared with baseline, significant reductions in noninflammatory, inflammatory, and total lesions were seen in the first 4 weeks of treatment with CL-BP 3.75%.

Alexithymia reversal was higher in patients who achieved control of their psoriasis, and reversal was associated with significant improvements in quality of life, anxiety, and depression.

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.